CFT1946

DRUG2 trials

Sponsors

C4 Therapeutics Inc., C4 Therapeutics, Inc.

Conditions

ATCBRAF-V600 Mutant Solid Tumors including MelanomaCRCColorectal cancer and Anaplastic thyroid carcinoma.MelanomaNSCLCNon-small cell lung cancerSolid Tumors

Phase 1

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

CompletedNCT05668585

C4 Therapeutics, Inc.ATC, CRC, Melanoma +2

Start: 2022-12-08End: 2025-11-05Updated: 2025-11-21

A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects with BRAF-V600 Mutant Solid Tumors.

CompletedCTIS2022-501618-70-00

C4 Therapeutics Inc.BRAF-V600 Mutant Solid Tumors including Melanoma, Colorectal cancer and Anaplastic thyroid carcinoma., Non-small cell lung cancer

Start: 2023-06-27End: 2025-10-08Target: 59Updated: 2025-08-28

Related Papers

Abstract 1658: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis

Cancer Research2024-03-22

A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.

Journal of Clinical Oncology2023-06-0115 citations